Raja R Narayan1,2, Debra A Goldman3, Mithat Gonen3, Jonathan Reichel4, Kety H Huberman4, Sandeep Raj4, Agnes Viale4, Nancy E Kemeny5, Peter J Allen1, Vinod P Balachandran1, Michael I D'Angelica1, Ronald P DeMatteo1, Jeffrey A Drebin1, William R Jarnagin1, T Peter Kingham6. 1. Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kinghamt@mskcc.org.
Abstract
BACKGROUND: Liver resection can be curative for well-selected metastatic colorectal cancer (CRC) patients. Circulating tumor DNA (ctDNA) has shown promise as a biomarker for tumor dynamics and recurrence following CRC resection. This prospective pilot study investigated the use of ctDNA to predict disease outcome in resected CRC patients. METHODS: Between November 2014 and November 2015, 60 patients with CRC were identified and prospectively enrolled. During liver resection, blood was drawn from peripheral (PERIPH), portal (PV), and hepatic (HV) veins, and 3-4 weeks postoperatively from a peripheral vein (POSTOP). Kappa statistics were used to compare mutated (mt) genes in tissue and ctDNA. Disease-specific and disease-free survival (DSS and DFS) were assessed from surgery with Kaplan-Meier and Cox methods. RESULTS: For the 59 eligible patients, the most commonly mutated genes were TP53 (mtTP53: 47.5%) and APC (mtAPC: 50.8%). Substantial to almost-perfect agreement was seen between ctDNA from PERIPH and PV (mtTP53: 89.8%, κ = 0.73, 95% confidence interval [CI] 0.53-0.93; mtAPC: 94.9%, κ = 0.83, 95% CI 0.64-1.00), as well as HV (mtTP53: 91.5%, κ = 0.78, 95% CI 0.60-0.96; mtAPC: 91.5%, κ = 0.73, 95% CI 0.51-0.95). Tumor mutations and PERIPH ctDNA had fair-to-moderate agreement (mtTP53: 72.9%, κ = 0.44, 95% CI 0.23-0.66; mtAPC: 61.0%, κ = 0.23, 95% CI 0.04-0.42). Detection of PERIPH mtTP53 was associated with worse 2-year DSS (mt+ 79% vs. mt- 90%, P = 0.024). CONCLUSIONS: Peripheral blood reflects the perihepatic ctDNA signature. Disagreement between tissue and ctDNA mutations may reflect the true natural history of tumor genes or an assay limitation. Peripheral ctDNA detection before liver resection is associated with worse DSS.
BACKGROUND: Liver resection can be curative for well-selected metastatic colorectal cancer (CRC) patients. Circulating tumor DNA (ctDNA) has shown promise as a biomarker for tumor dynamics and recurrence following CRC resection. This prospective pilot study investigated the use of ctDNA to predict disease outcome in resected CRC patients. METHODS: Between November 2014 and November 2015, 60 patients with CRC were identified and prospectively enrolled. During liver resection, blood was drawn from peripheral (PERIPH), portal (PV), and hepatic (HV) veins, and 3-4 weeks postoperatively from a peripheral vein (POSTOP). Kappa statistics were used to compare mutated (mt) genes in tissue and ctDNA. Disease-specific and disease-free survival (DSS and DFS) were assessed from surgery with Kaplan-Meier and Cox methods. RESULTS: For the 59 eligible patients, the most commonly mutated genes were TP53 (mtTP53: 47.5%) and APC (mtAPC: 50.8%). Substantial to almost-perfect agreement was seen between ctDNA from PERIPH and PV (mtTP53: 89.8%, κ = 0.73, 95% confidence interval [CI] 0.53-0.93; mtAPC: 94.9%, κ = 0.83, 95% CI 0.64-1.00), as well as HV (mtTP53: 91.5%, κ = 0.78, 95% CI 0.60-0.96; mtAPC: 91.5%, κ = 0.73, 95% CI 0.51-0.95). Tumor mutations and PERIPH ctDNA had fair-to-moderate agreement (mtTP53: 72.9%, κ = 0.44, 95% CI 0.23-0.66; mtAPC: 61.0%, κ = 0.23, 95% CI 0.04-0.42). Detection of PERIPH mtTP53 was associated with worse 2-year DSS (mt+ 79% vs. mt- 90%, P = 0.024). CONCLUSIONS: Peripheral blood reflects the perihepatic ctDNA signature. Disagreement between tissue and ctDNA mutations may reflect the true natural history of tumor genes or an assay limitation. Peripheral ctDNA detection before liver resection is associated with worse DSS.
Authors: Long R Jiao; Christos Apostolopoulos; Jimmy Jacob; Richard Szydlo; Natalia Johnson; Nicole Tsim; Nagy A Habib; R Charles Coombes; Justin Stebbing Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Frank Diehl; Meng Li; Devin Dressman; Yiping He; Dong Shen; Steve Szabo; Luis A Diaz; Steven N Goodman; Kerstin A David; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein Journal: Proc Natl Acad Sci U S A Date: 2005-10-28 Impact factor: 11.205
Authors: Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway Journal: Nat Genet Date: 2007-02-11 Impact factor: 38.330
Authors: Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Thierry Lecomte; Anne Berger; Franck Zinzindohoué; Stéphanie Micard; Bruno Landi; Hélène Blons; Philippe Beaune; Paul-Henri Cugnenc; Pierre Laurent-Puig Journal: Int J Cancer Date: 2002-08-10 Impact factor: 7.396
Authors: Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz Journal: Nat Med Date: 2007-07-31 Impact factor: 53.440
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2022-07-27 Impact factor: 4.339
Authors: Florian E Buisman; Boris Galjart; Eric P van der Stok; Nancy E Kemeny; Vinod P Balachandran; Thomas Boerner; Andrea Cercek; Dirk J Grünhagen; William R Jarnagin; T Peter Kingham; Cornelis Verhoef; B Groot Koerkamp; Michael I D'Angelica Journal: HPB (Oxford) Date: 2019-12-27 Impact factor: 3.647
Authors: Raja R Narayan; Victoria G Aveson; Joanne F Chou; Henry S Walch; Francisco Sanchez-Vega; Gustavo Dos Santos Fernandes; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; Andrea Cercek; Mithat Gönen; Nikolaus Schultz; T Peter Kingham Journal: J Surg Oncol Date: 2022-01-23 Impact factor: 2.885
Authors: Karen Gambaro; Maud Marques; Suzan McNamara; Mathilde Couetoux du Tertre; Zuanel Diaz; Cyrla Hoffert; Archana Srivastava; Steven Hébert; Benoit Samson; Bernard Lespérance; Yoo-Joung Ko; Richard Dalfen; Eve St-Hilaire; Lucas Sideris; Felix Couture; Ronald Burkes; Mohammed Harb; Errol Camlioglu; Adrian Gologan; Vincent Pelsser; André Constantin; Celia M T Greenwood; Sabine Tejpar; Petr Kavan; Claudia L Kleinman; Gerald Batist Journal: Clin Transl Med Date: 2021-04
Authors: Jun Gong; Andrew Hendifar; Alexandra Gangi; Karen Zaghiyan; Katelyn Atkins; Yosef Nasseri; Zuri Murrell; Jane C Figueiredo; Sarah Salvy; Robert Haile; Megan Hitchins Journal: Cancers (Basel) Date: 2021-09-10 Impact factor: 6.639